Highest-materiality recent filing
Beam Therapeutics Q2 net loss $122.7M; first patient dosed in BEAM-302 pivotal trial
Net loss of $122.7M ($1.18 per share) vs $102.1M loss in Q2 2025; R&D expenses $95.1M.
Beam Therapeutics 2026 annual meeting results: all director nominees and proposals approved
John Evans, John Maraganore, and Christi Shaw elected as Class III directors with 71.7M, 64.8M, and 65.7M votes for respectively.
Beam Therapeutics Reports Q1 2026 Results; BEAM-302 Pivotal Cohort and Risto-cel BLA on Track
BEAM-302 Phase 1/2 data showed single-dose safety and efficacy; 60 mg selected as optimal dose; global pivotal cohort to start H2 2026.
Beam terminates license pact with Bio Palette; Kobe University standby license activated
Mutual termination of License Agreement with Bio Palette effective March 2, 2026 due to Bio Palette's planned dissolution.
Q4 net income $244.3M ($2.33 diluted EPS); full-year net loss $80.0M ($0.81 per share).
Beam Therapeutics secures standby direct license to Kobe University patents for base editing
Agreement dated Feb 9, 2026 among Beam, Bio Palette, and Kobe University ensures backup patent access.
Director Carole Ho resigns from Beam Therapeutics board effective Feb 27, 2026
Carole Ho notified resignation on Jan 31, 2026, effective Feb 27, 2026.
Estimated $1.25B cash, cash equivalents and marketable securities as of Dec 31, 2025; operating runway extended into 2029.
Beam Therapeutics nets $255.1M cash from sale of Orbital stake in BMS acquisition
Beam received $255.1M in closing cash plus up to ~$26.3M from escrow for its 75M shares (17% fully diluted) of Orbital.
Beam Q3 net loss $112.7M; cash $1.1B; BEAM-302 expands; Orbital acquisition by BMS
Net loss of $112.7M ($1.10 per share) in Q3 2025 vs $96.7M ($1.17 per share) in Q3 2024.
Beam Q2 net loss $102.3M; cash $1.2B; BEAM-302 17 patients dosed; BEAM-101 enrollment complete
Net loss of $102.3M ($1.00/share) vs $91.1M loss ($1.11/share) in Q2 2024; R&D expense rose to $101.8M.
Upfront consideration: 403,128 shares of BEAM common stock (~$6.86M based on $17.01 close).
Beam Therapeutics shareholders elect directors, ratify Deloitte, approve say-on-pay
Elected Mark Fishman (61.9M for, 10.3M against), Carole Ho (71.7M for), and Kathleen Walsh (71.9M for) as Class II directors.
Beam Q1 net loss $109.3M; cash $1.2B after $500M financing; clinical milestones hit
Net loss $109.3M ($1.24/share) vs $98.7M ($1.21/share) Q1 2024; R&D spend $98.8M.
BEAM-302 well tolerated at all doses; no serious AEs or dose-limiting toxicities observed.
Beam prices $500M underwritten offering of common stock and pre-funded warrants
Underwritten offering of 16,151,686 shares at $28.48 per share and pre-funded warrants for 1,404,988 shares at $28.47 each.
Beam Therapeutics reports Q4 net loss of $90.4M; cash $850.7M, clinical milestones reaffirmed
Net loss per share $1.09 in Q4 2024 vs net income of $1.77 in Q4 2023; full-year net loss $4.58 per share vs $1.72 in 2023.
Beam Therapeutics: $850.7M cash, pipeline progress, 2025 catalysts detailed
Preliminary cash, equivalents and marketable securities of $850.7M as of Dec 31, 2024; runway now into 2027 including BEAM-101 commercial readiness.
Seven patients dosed with BEAM-101 achieved HbF >60%, HbS <40%, and resolution of anemia; no VOCs post-engraftment.
Beam Therapeutics appoints Sravan Emany as CFO effective Dec 19, 2024
Sravan Emany previously CFO/COO of Ironwood Pharmaceuticals; also held roles at Integra, Bank of America, Goldman Sachs.
Beam Therapeutics appoints Chirfi Guindo to board of directors
Chirfi Guindo, chief marketing officer of Human Health at Merck, appointed to Beam's board.
Beam Therapeutics Q3 net loss $96.7M; cash $925.8M; BEAM-101 enrollment at 35 patients
Net loss $96.7M ($1.17/share) vs $96.1M ($1.22) Q3 2023; R&D $94.3M, G&A $26.5M.
Beam Therapeutics discusses Q3 results and ASH abstracts on investor call
Investor presentation covered Q3 financial results, but no specific figures provided in filing.
BEAM-101 (sickle cell disease): 4 patients engrafted, median 17 days neutrophil, 20 days platelet; HbF >60% by month 1.
Beam Therapeutics Q2 net loss $91.1M; cash $1.0B; BEAM-101 enrollment tops 20, six dosed
Net loss widened to $91.1M ($1.11/shr) from $82.8M ($1.08/shr) in Q2 2023.
CFO Terry-Ann Burrell resigns effective Aug 9, 2024 to join JPMorgan as vice chairman of investment banking.
Graham Cooper elected to board with 49.5M for, 6.5M against, 1.8M abstain, 8.4M broker non-votes.
Beam Therapeutics Q1 net loss $98.7M; BEAM-101 expansion cohort opened, cash $1.1B into 2027
Net loss of $98.7M ($1.21 per share) vs $96.5M ($1.33 per share) in Q1 2023.
Beam Therapeutics Q4 net income $142.8M; cash $1.2B, runway to 2027
Q4 net income $142.8M ($1.77 basic EPS) vs net loss $38.3M in Q4 2022; full-year net loss $132.5M vs $289.1M loss in 2022.
Beam dosed first SCD patient, submitted CTA for AATD, cash $1.2B into 2027
First patient dosed in BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease; initial data expected H2 2024.
Beam Therapeutics appoints Christi Shaw, former Kite CEO, to board of directors
Board expanded from 7 to 8 members; Shaw appointed as Class III director with term until 2026.
Beam Q3 2023: net loss $96.1M, Lilly deal up to $600M, pipeline on track
Net loss of $96.1M ($1.22 per share) vs $109.6M ($1.56) in Q3 2022; R&D $100M, G&A $25.4M.
Beam sells opt-in rights on Verve CVD programs to Lilly for $200M + $50M equity; up to $600M total
Beam receives $200M upfront and $50M equity (2,004,811 shares at $24.94, 15% premium to 30-day VWAP).
Beam cuts ~20% workforce (100 roles), focuses on sickle cell, AATD, extends cash runway into 2026
Reduces headcount by ~100 employees (20%), expects $6.6M in Q4 2023 severance costs.
Beam Q2 net loss $82.8M; BEAM-101/201 trials advance, in vivo programs accelerated
Q2 net loss $82.8M ($1.08/shr) vs $72.0M ($1.02/shr) in Q2 2022; R&D spend $97.6M (up 31% YoY).
John Evans elected with 48.7M for, 250k against; John Maraganore with 41.6M for, 7.4M against.
Beam Q1 net loss $96.5M ($1.33/sh); BEACON trial advancing, BEAM-201 on track
Net loss $96.5M ($1.33/sh) vs $69.2M ($1.01/sh) YoY; R&D spend up to $99.6M.
Beam Therapeutics increases ATM equity offering capacity by $300M to $1.1B
Added $300M in capacity to existing $800M at-the-market equity offering with Jefferies.
Beam Therapeutics reports Q4 2022 net loss of $38.3M; cash at $1.1B, runway into 2025
Net loss Q4 2022: $38.3M ($0.54/share) vs $64.7M ($0.95/share) in Q4 2021; full year net loss $289.1M ($4.13/share).
Beam Therapeutics reports pipeline progress, ~$1B cash, and outlines milestones for 2023-2024
Estimated $1.0B cash, cash equivalents, and marketable securities as of Dec 31, 2022; cash runway expected into 2025.
Beam Therapeutics Q3 net loss $109.6M; BEACON trial enrollment started for BEAM-101
Net loss $109.6M ($1.56/sh) vs $28.1M ($0.42/sh) in Q3 2021; R&D spend $85.3M.
Beam Therapeutics enters license collaboration with Orbital; will consolidate it financially
Beam receives 75M shares of Orbital common stock; expects to consolidate Orbital under ASC 810.
Beam announces FDA formal clinical hold letter for BEAM-201 IND; plans Q4 2022 response
FDA placed BEAM-201 IND on clinical hold for relapsed/refractory T-ALL/T-LBL.
Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B
Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).
FDA places clinical hold on Beam's BEAM-201 IND for T-ALL/T-LL
FDA clinical hold on BEAM-201 IND for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma.
Beam Therapeutics shareholders elect three Class II directors, ratify auditor, approve say-on-pay
All three director nominees (Fishman, Ho, Walsh) elected with ~39.5M votes each.
Beam Therapeutics Q1 net loss $69.2M; cash $1.2B; pipeline on track for H2 2022
Net loss $69.2M ($1.01 per share) vs $201.6M ($3.35) in Q1 2021 due to prior-year in-process R&D charge.
Beam reports $1.2B cash post-Pfizer deal; H2 2022 IND milestones set for SCD programs
Pfizer collaboration: $300M upfront, up to $1.35B milestones for in vivo base editing programs.
Beam Therapeutics enters $1.35B collaboration with Pfizer for in vivo base editing programs
Exclusive 4-year collaboration with Pfizer on 3 rare disease targets (liver, muscle, CNS).
Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M
FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.
Effective upon Ms. Burrell’s resignation, John Evans, the Company’s Chief Executive Officer and a member of the Company’s board of directors, was appointed Principal Financial and Accounting Officer of the Company.
Terry-Ann Burrell notified Beam Therapeutics Inc. (the “Company”) of her decision to resign as Chief Financial Officer and Treasurer of the Company, effective August 9, 2024, to pursue other opportunities.
On December 13, 2023, the Board of Directors (the “Board”) of Beam Therapeutics Inc. (the “Company”), upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from seven to eight members and elected Christi Shaw as a member of the Board.
On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.
Max materiality 0.85 · Median 0.70 · Most common event earnings